查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1471213

疫苗契約製造市場：按類型、特徵和應用分類 - 2024-2030 年全球預測

Vaccine Contract Manufacturing Market by Type (Attenuated Vaccine, DNA Vaccines, Inactivated Vaccine), Function (Downstream, Upstream), Application - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

疫苗契約製造市場規模預計2023年為50.6億美元，2024年達到55.1億美元，預計2030年將達到93.9億美元，複合年成長率為9.21%。

疫苗契約製造是指將疫苗製造過程外包給稱為受託製造廠商（CMO）的第三方。這些專業公司擁有在從最初開發到全面生產和包裝的各個階段生產疫苗的專業知識、設備和設施。疫苗製造商與 CMO 合作，加速開發和製造流程、利用專業知識、控制成本並確保供應鏈彈性。疫苗契約製造市場包括以合約形式向製藥業提供各種服務的公司。這包括各階段的疫苗生產，從臨床前測試等早期開發到大規模商業生產。這通常包括抗原製造等上游工程和填充、精加工和包裝等下游製程。疫苗契約製造是需要額外疫苗生產能力和專業知識的製藥公司、生物技術公司和研究機構的重要合作夥伴。在全球感染疾病數量增加、政府對疫苗開發的監管和支持加強以及新生兒和兒童疫苗接種增加的背景下，疫苗的契約製造正在成長。然而，市場面臨某些挑戰，包括疫苗相關的高成本和缺乏適當的儲存基礎設施。同時，mRNA疫苗技術的進步以及與政府和非政府組織的戰略聯盟與合作正在為疫苗契約製造市場創造潛在的商機。

主要市場統計
基準年[2023] 50.6億美元
預測年份 [2024] 55.1億美元
預測年份 [2030] 93.9億美元
複合年成長率（%） 9.21%

類型：更多地採用減毒疫苗來增強免疫系統

減毒疫苗使用活病毒疫苗的、弱化的病毒或細菌，不會對免疫系統健康的人造成疾病。這種類型的疫苗會產生強烈的免疫反應，通常需要較少的劑量即可獲得長期免疫力。 DNA 疫苗利用病原體的部分遺傳物質來引發免疫反應。這種藥物使體內細胞產生病原體特異性抗原並刺激特異性免疫反應。 DNA 疫苗仍然是一項相對較新的技術，在開發速度和穩定性方面具有潛在優勢，使其成為契約製造的有趣途徑。去活化疫苗含有已透過物理或化學處理殺死的病毒或細菌。這些疫苗本身不存在引起疾病的風險，並且穩定，適合多種環境。去活化疫苗通常需要佐劑來增強免疫反應，並且可能需要多次劑量。次單位疫苗僅包含病毒或細菌的必需抗原，而不是整個病原體。這種方法最大限度地減少了副作用的風險，當病原體無法在試管內培養或不需要接種整個生物體時特別有用。類毒素疫苗是由致病細菌產生的去活化有毒化合物，而不是細菌本身。這些疫苗訓練免疫系統抵抗天然毒素，並在免疫者遇到實際病原體時提供保護。這種疫苗對產生毒素是導致疾病的主要原因的細菌特別有效，例如導致破傷風的破傷風梭菌。

功能：增加下游製劑的使用，涉及生物製品的精製和製劑

下游加工是指疫苗生產中對大宗產品進行精製和精製以滿足監管標準和品質要求的階段。關鍵的下游步驟包括細胞和病毒顆粒分離、污染物去除以及疫苗濃縮和配製。下游加工的需求源於在向公眾施用疫苗之前確保疫苗的安全性、純度和有效性的需要。疫苗生產的上游工程包括疫苗生產生系統的繁殖和初始收穫所需的所有步驟。這通常涉及培養產生疫苗抗原的細胞或微生物。對尖端上游工程技術的偏好源於對一致、可擴展和高產量疫苗生產的基本需求。

應用：疫苗的契約製造越來越有可能用於人類，以保護人們免受感染疾病。

人類疫苗契約製造的需求主要是由世界保護人們免受感染疾病的需要所驅動的。該部門包括生產適用於各種情況的疫苗，從每年的流感疫苗注射到針對新出現的公共衛生威脅（包括 COVID-19）的免疫接種。獸用疫苗的疫苗契約製造可滿足動物群體（包括牲畜和伴同性動物）的疫苗接種需求。該部分保證動物健康，這對於糧食安全和預防感染人類的通用感染疾病至關重要。

區域洞察

美洲地區擁有美國、加拿大等國家，醫療體系先進，居民健康意識較高。美國是疫苗研究的著名國家。生物專利生態系統充滿活力，政府、工業界和學術界積極投資新疫苗技術。在南美洲，生物技術投資的增加、政府對藥品生產的激勵措施、公共衛生支出的增加以及生物製造設施的存在正在推動疫苗契約製造的採用。歐洲擁有成熟的疫苗契約製造製造業，受益於高品質的製造標準和嚴格的監管環境。歐盟（EU）國家積極從事研究和創新，擁有強大的生物技術公司和研究機構網路。中東地區歷來依賴進口疫苗，但目前正逐步發展疫苗生產能力，阿拉伯聯合大公國和沙烏地阿拉伯等國投資建設當地生產設施。非洲市場深受全球衛生舉措和合作夥伴關係的影響，這些計劃和合作夥伴關係致力於為各種經濟背景的人們提供疫苗。由於人口眾多、醫療保健支出不斷增加以及人們對疫苗接種需求的認知不斷增強，亞太地區是一個充滿活力且快速成長的市場。印度和中國等國家處於領先地位，擁有重要的生產設施，為世界疫苗供應做出了貢獻。中國正大力投資生技和疫苗創新，強調技術升級的重要性。日本公司正在投資下一代疫苗，包括基於 mRNA 和 DNA 的疫苗，政府也正在透過措施支持研究。

FPNV定位矩陣

FPNV定位矩陣對於評估疫苗契約製造市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標，以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估，供應商被分為四個成功程度不同的像限。最前線 (F)、探路者 (P)、利基 (N) 和重要 (V)。

市場佔有率分析

市場佔有率分析是一種綜合工具，可以對疫苗契約製造市場供應商的現狀進行深入而深入的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻，以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外，該分析還提供了對該細分市場競爭特徵的寶貴見解，包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略，從而在市場上獲得競爭優勢。

本報告在以下方面提供了寶貴的見解：

1. 市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2. 市場開拓：我們深入研究利潤豐厚的新興市場，並分析其在成熟細分市場的滲透率。

3. 市場多元化：包括新產品發布、開拓地區、最新發展和投資的詳細資訊。

4.競爭力評估與資訊：對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況、製造能力等進行全面評估。

5. 產品開發與創新：包括對未來技術、研發活動以及突破性產品開發的見解。

本報告解決了以下關鍵問題：

1.疫苗契約製造市場的市場規模與預測為何？

2.在疫苗契約製造市場的預測期內，我們應該考慮投資哪些產品和應用？

3.疫苗契約製造市場的技術趨勢和法規結構是什麼？

4.疫苗契約製造市場主要廠商的市場佔有率是多少？

5.進入疫苗契約製造市場的合適形式和策略手段是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 疫苗需求增加擴大了合約製造商的產能
      • 合約服務的主要好處包括節省成本和時間
      • 世界各地的疫苗接種率
    • 抑制因素
      • 成熟疫苗製造商的有限外包
    • 機會
      • 全球需求不斷成長，以滿足不斷成長的不同年齡層人口的需求
      • 創新和強大的疫苗產品線
      • 政府對加速疫苗生產的有利觀點和指導方針
    • 任務
      • 製藥公司在內部進行生產業務以獲得策略控制
  • 市場區隔分析
    • 類型：更多地採用減毒疫苗來增強免疫系統
    • 特點：增加下游加工配方的使用，包括生物產品精製和配方
    • 應用：增加人類用於保護人們免受感染疾病的疫苗契約製造的潛力
  • 市場擾動分析
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 價格分析
  • 技術分析
  • 專利分析
  • 貿易分析
  • 法規結構分析

第6章 疫苗契約製造市場：依類型

  • 介紹
  • 減毒疫苗
  • DNA疫苗
  • 去活化疫苗
  • 次單位疫苗
  • 類毒素疫苗

第7章 疫苗契約製造市場：依功能分類

  • 介紹
  • 下游
  • 上游

第8章疫苗契約製造市場：依應用分類

  • 介紹
  • 對於人類
  • 獸醫

第9章 北美和南美疫苗契約製造市場

  • 介紹
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太疫苗契約製造市場

  • 介紹
  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章 歐洲、中東和非洲疫苗契約製造市場

  • 介紹
  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

第13章競爭產品組合

  • 主要企業簡介
  • 主要產品系列
Product Code: MRR-430D42AA0DC4

[199 Pages Report] The Vaccine Contract Manufacturing Market size was estimated at USD 5.06 billion in 2023 and expected to reach USD 5.51 billion in 2024, at a CAGR 9.21% to reach USD 9.39 billion by 2030.

Vaccine contract manufacturing refers to outsourcing vaccine production processes to third-party organizations, known as contract manufacturing organizations (CMOs). These specialized companies possess the expertise, equipment, and facilities to produce vaccines at various stages, from initial development to full-scale production and packaging. Vaccine manufacturers partner with CMOs to expedite the development and manufacturing process, leverage specialized capabilities, manage costs, and ensure supply chain flexibility. The vaccine contract manufacturing market encompasses companies that provide a range of services on a contract basis for the pharmaceutical industry. This includes the production of vaccines at various stages, from early-stage development, such as preclinical trials, through to large-scale commercial production. It often involves upstream processes, such as antigen production, and downstream processes, including filling, finishing, and packaging. Vaccine contract manufacturers serve as critical partners for pharmaceutical firms, biotechnology companies, and research institutions that require additional capability or expertise in vaccine production. The vaccine contract manufacturing is growing due to increasing outbreaks of infectious diseases worldwide, growing governmental regulations and support for vaccine development, and rising vaccinations of newborns and children. However, the market faces certain challenges, such as the high cost associated with vaccines and the lack of proper storage infrastructure. On the other hand, technological advancements in mRNA vaccine technology and strategic partnerships and collaborations with governments and non-governmental organizations present potential opportunities for the vaccine contract manufacturing market.

KEY MARKET STATISTICS
Base Year [2023] USD 5.06 billion
Estimated Year [2024] USD 5.51 billion
Forecast Year [2030] USD 9.39 billion
CAGR (%) 9.21%

Type: Growing adoption of attenuated vaccines to enhance immune systems

An attenuated vaccine uses a live version of the virus or bacteria that has been weakened, which cannot cause disease in people with healthy immune systems. This type of vaccine elicits a strong immune response and often requires fewer doses for long-term immunity. DNA vaccines employ a piece of genetic material from a pathogen to elicit an immune response. They direct the body's cells to produce an antigen that is native to the pathogen, prompting a specific immune response. DNA vaccines are still a relatively new technology and offer potential advantages in speed of development and stability, making them an interesting avenue for contract manufacturing. Inactivated vaccines contain viruses or bacteria that have been killed through physical or chemical processes. These vaccines do not pose a risk of causing the disease itself and are stable, making them suitable for a broad range of environments. Inactivated vaccines generally require adjuvants to enhance the immune response and may require multiple doses. Subunit vaccines include only the essential antigens of a virus or bacteria-rather than the whole pathogen. This approach minimizes the risk of side effects and is particularly useful when the pathogen cannot be cultivated in vitro or when the whole organism is unnecessary for immunization. Toxoid vaccines contain inactivated toxic compounds produced by bacteria that cause illness rather than the bacteria itself. These vaccines train the immune system to fight off the natural toxin, offering protection if the immunized individual ever encounters the actual pathogen. They are particularly useful for bacteria, such as Clostridium tetani, the cause of tetanus, where toxin production is the main cause of disease.

Function: Increasing usage of downstream processing formulations that involve the purification and formulation of the bioproducts

Downstream processing refers to the phase of vaccine manufacturing where the bulk product is refined and purified to meet regulatory standards and quality requirements. Key steps in downstream processing include the separation of cells and virus particles, removal of contaminants, and concentration and formulation of the vaccine. The need for downstream processing arises from the necessity to ensure that vaccines are safe, pure, and effective before they can be administered to the public. Upstream processing in vaccine manufacturing includes all steps necessary for the growth and initial harvest of the vaccine-producing biological system. This generally involves the culturing of cells or microorganisms that generate the vaccine antigen. The preference for cutting-edge upstream processing technologies stems from the fundamental need for consistent, scalable, and high-yield vaccine production.

Application: Rising potential of vaccine contract manufacturing for human use to protect populations against infectious diseases

The need for vaccine contract manufacturing in the human use segment is primarily driven by the global need to protect populations against infectious diseases. This segment encompasses the production of vaccines for a vast range of conditions, from annual influenza shots to immunizations against emerging public health threats, including COVID-19. Vaccine contract manufacturing for veterinary applications addresses the need for immunizations within animal populations, including both livestock and companion animals. The segment ensures the health of animals, which is crucial for food security and the prevention of zoonotic diseases that can transfer to humans.

Regional Insights

The Americas region, with countries such as the United States and Canada, is characterized by advanced healthcare systems and a high degree of health awareness among the population. The United States stands as a prominent country in vaccine research. It has a vibrant ecosystem for biotech patents, with the government, industry, and academia actively investing in new vaccine technologies. In South America, increasing investment in biotechnology, government incentives for pharmaceutical manufacturing, growing public health expenditure, and the presence of bio-manufacturing facilities support the adoption of vaccine contract manufacturing. Europe has a mature vaccine contract manufacturing industry, benefiting from high-quality manufacturing standards and a stringent regulatory landscape. European Union (EU) countries actively engage in research and innovation, with a strong network of biotech firms and research institutes. The Middle East, while historically reliant on imported vaccines, is gradually developing its vaccine manufacturing capabilities, with nations including the United Arab Emirates and Saudi Arabia investing in local production facilities. Africa's market is heavily influenced by global health initiatives and partnerships focused on providing access to vaccines for all economic backgrounds. Asia Pacific represents a dynamic and rapidly growing vaccine contract manufacturing market due to its large population base, increasing healthcare expenditures, and growing awareness of the need for immunizations. Nations such as India and China are at the forefront, with a substantial number of manufacturing facilities contributing to the global vaccine supply. China has made significant investments in biotech and vaccine innovation, emphasizing the importance of technological upgrades. Japanese companies are investing in next-generation vaccines, including mRNA and DNA-based vaccines, while the government supports research through initiatives.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Vaccine Contract Manufacturing Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Vaccine Contract Manufacturing Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Vaccine Contract Manufacturing Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc, Ajinomoto Bio-Pharma Services by Ajinomoto Co., Inc., Aton (Shanghai) Biotech Co., Ltd., Avid Bioservices, Inc., Catalent, Inc., Charles River Laboratories International, Inc., CSL Limited, Curia Global, Inc., Cytovance Biologics by Shenzhen Hepalink Pharmaceutical Group Co., Ltd., Emergent BioSolutions Inc., FUJIFILM Diosynth Biotechnologies U.S.A., Inc. by FUJIFILM Corporation, Gedeon Richter PLC, GlaxoSmithKline PLC, ICON PLC, IDT Biologika GmbH, KBI Biopharma, Inc. by JSR Corporation, Klocke Pharma-Service GmbH, Lonza Group Ltd., Merck KGaA, Moderna, Inc., Pfizer Inc., Pharmaceutical Product Development by Thermo Fisher Scientific Inc., Recipharm AB, Serum Institute of India, and Vetter Pharma-Fertigung GmbH & Co. KG.

Market Segmentation & Coverage

This research report categorizes the Vaccine Contract Manufacturing Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Type
    • Attenuated Vaccine
    • DNA Vaccines
    • Inactivated Vaccine
    • Subunit Vaccines
    • Toxoid Vaccines
  • Function
    • Downstream
      • Analytical & QC studies
      • Fill & Finish Operations
      • Packaging
    • Upstream
      • Bacterial Expression Systems
      • Baculovirus or Insect Expression Systems
      • Mammalian Expression Systems
      • Yeast Expression Systems
  • Application
    • Human Use
    • Veterinary
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Vaccine Contract Manufacturing Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Vaccine Contract Manufacturing Market?

3. What are the technology trends and regulatory frameworks in the Vaccine Contract Manufacturing Market?

4. What is the market share of the leading vendors in the Vaccine Contract Manufacturing Market?

5. Which modes and strategic moves are suitable for entering the Vaccine Contract Manufacturing Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing demand for vaccines leading to capacity expansion by contract manufacturers
      • 5.1.1.2. Key advantages such as cost and time saving offered by contract services
      • 5.1.1.3. Vaccination coverage across the globe
    • 5.1.2. Restraints
      • 5.1.2.1. Limited outsourcing by well-established vaccine manufacturers
    • 5.1.3. Opportunities
      • 5.1.3.1. Rising global demand to cater to the growing population of varied age groups
      • 5.1.3.2. Innovation and robust vaccine pipeline
      • 5.1.3.3. Favorable government insights and guidelines to speed up the vaccine manufacturing
    • 5.1.4. Challenges
      • 5.1.4.1. Pharma companies manufacturing operations in-house to gain strategic control
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Growing adoption of attenuated vaccines to enhance immune systems
    • 5.2.2. Function: Increasing usage of downstream processing formulations that involve the purification and formulation of the bioproducts
    • 5.2.3. Application: Rising potential of vaccine contract manufacturing for human use to protect populations against infectious diseases
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Vaccine Contract Manufacturing Market, by Type

  • 6.1. Introduction
  • 6.2. Attenuated Vaccine
  • 6.3. DNA Vaccines
  • 6.4. Inactivated Vaccine
  • 6.5. Subunit Vaccines
  • 6.6. Toxoid Vaccines

7. Vaccine Contract Manufacturing Market, by Function

  • 7.1. Introduction
  • 7.2. Downstream
  • 7.3. Upstream

8. Vaccine Contract Manufacturing Market, by Application

  • 8.1. Introduction
  • 8.2. Human Use
  • 8.3. Veterinary

9. Americas Vaccine Contract Manufacturing Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Vaccine Contract Manufacturing Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Vaccine Contract Manufacturing Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Vaxcyte and Lonza Expand Collaboration for Global Commercial Manufacturing of Broad-Spectrum Pneumococcal Conjugate Vaccines (PCVs)
    • 12.3.2. Oxford Acquires ABL Europe From Institut Merieux For EUR 15 Mn
    • 12.3.3. Pfizer Inks USD 183M Contract Manufacturing Deal With Samsung Biologics
  • 12.4. Strategy Analysis & Recommendation

13. Competitive Portfolio

  • 13.1. Key Company Profiles
  • 13.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. VACCINE CONTRACT MANUFACTURING MARKET RESEARCH PROCESS
  • FIGURE 2. VACCINE CONTRACT MANUFACTURING MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. VACCINE CONTRACT MANUFACTURING MARKET DYNAMICS
  • FIGURE 7. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. VACCINE CONTRACT MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 22. VACCINE CONTRACT MANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. VACCINE CONTRACT MANUFACTURING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY ATTENUATED VACCINE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY ATTENUATED VACCINE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DNA VACCINES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DNA VACCINES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY INACTIVATED VACCINE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY INACTIVATED VACCINE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SUBUNIT VACCINES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SUBUNIT VACCINES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TOXOID VACCINES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TOXOID VACCINES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL & QC STUDIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL & QC STUDIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FILL & FINISH OPERATIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FILL & FINISH OPERATIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY PACKAGING, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY PACKAGING, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY BACTERIAL EXPRESSION SYSTEMS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY BACTERIAL EXPRESSION SYSTEMS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY BACULOVIRUS OR INSECT EXPRESSION SYSTEMS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY BACULOVIRUS OR INSECT EXPRESSION SYSTEMS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY MAMMALIAN EXPRESSION SYSTEMS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY MAMMALIAN EXPRESSION SYSTEMS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY YEAST EXPRESSION SYSTEMS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY YEAST EXPRESSION SYSTEMS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 43. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 44. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 45. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY HUMAN USE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 46. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY HUMAN USE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 47. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VETERINARY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 48. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VETERINARY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 49. AMERICAS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 50. AMERICAS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 51. AMERICAS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 52. AMERICAS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 53. AMERICAS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2023 (USD MILLION)
  • TABLE 54. AMERICAS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2024-2030 (USD MILLION)
  • TABLE 55. AMERICAS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2023 (USD MILLION)
  • TABLE 56. AMERICAS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2024-2030 (USD MILLION)
  • TABLE 57. AMERICAS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 58. AMERICAS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 59. AMERICAS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 60. AMERICAS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 61. ARGENTINA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 62. ARGENTINA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 63. ARGENTINA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 64. ARGENTINA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 65. ARGENTINA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2023 (USD MILLION)
  • TABLE 66. ARGENTINA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2024-2030 (USD MILLION)
  • TABLE 67. ARGENTINA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2023 (USD MILLION)
  • TABLE 68. ARGENTINA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2024-2030 (USD MILLION)
  • TABLE 69. ARGENTINA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 70. ARGENTINA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 71. BRAZIL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 72. BRAZIL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 73. BRAZIL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 74. BRAZIL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 75. BRAZIL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2023 (USD MILLION)
  • TABLE 76. BRAZIL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2024-2030 (USD MILLION)
  • TABLE 77. BRAZIL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2023 (USD MILLION)
  • TABLE 78. BRAZIL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2024-2030 (USD MILLION)
  • TABLE 79. BRAZIL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 80. BRAZIL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 81. CANADA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 82. CANADA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 83. CANADA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 84. CANADA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 85. CANADA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2023 (USD MILLION)
  • TABLE 86. CANADA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2024-2030 (USD MILLION)
  • TABLE 87. CANADA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2023 (USD MILLION)
  • TABLE 88. CANADA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2024-2030 (USD MILLION)
  • TABLE 89. CANADA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 90. CANADA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 91. MEXICO VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 92. MEXICO VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 93. MEXICO VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 94. MEXICO VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 95. MEXICO VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2023 (USD MILLION)
  • TABLE 96. MEXICO VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2024-2030 (USD MILLION)
  • TABLE 97. MEXICO VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2023 (USD MILLION)
  • TABLE 98. MEXICO VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2024-2030 (USD MILLION)
  • TABLE 99. MEXICO VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 100. MEXICO VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 101. UNITED STATES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 102. UNITED STATES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 103. UNITED STATES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 104. UNITED STATES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 105. UNITED STATES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2023 (USD MILLION)
  • TABLE 106. UNITED STATES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2024-2030 (USD MILLION)
  • TABLE 107. UNITED STATES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2023 (USD MILLION)
  • TABLE 108. UNITED STATES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2024-2030 (USD MILLION)
  • TABLE 109. UNITED STATES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 110. UNITED STATES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 111. UNITED STATES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 112. UNITED STATES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2023 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2024-2030 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2023 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2024-2030 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 125. AUSTRALIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 126. AUSTRALIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 127. AUSTRALIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 128. AUSTRALIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 129. AUSTRALIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2023 (USD MILLION)
  • TABLE 130. AUSTRALIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2024-2030 (USD MILLION)
  • TABLE 131. AUSTRALIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2023 (USD MILLION)
  • TABLE 132. AUSTRALIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2024-2030 (USD MILLION)
  • TABLE 133. AUSTRALIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 134. AUSTRALIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 135. CHINA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 136. CHINA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 137. CHINA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 138. CHINA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 139. CHINA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2023 (USD MILLION)
  • TABLE 140. CHINA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2024-2030 (USD MILLION)
  • TABLE 141. CHINA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2023 (USD MILLION)
  • TABLE 142. CHINA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2024-2030 (USD MILLION)
  • TABLE 143. CHINA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 144. CHINA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 145. INDIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 146. INDIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 147. INDIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 148. INDIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 149. INDIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2023 (USD MILLION)
  • TABLE 150. INDIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2024-2030 (USD MILLION)
  • TABLE 151. INDIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2023 (USD MILLION)
  • TABLE 152. INDIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2024-2030 (USD MILLION)
  • TABLE 153. INDIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 154. INDIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 155. INDONESIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 156. INDONESIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 157. INDONESIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 158. INDONESIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 159. INDONESIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2023 (USD MILLION)
  • TABLE 160. INDONESIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2024-2030 (USD MILLION)
  • TABLE 161. INDONESIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2023 (USD MILLION)
  • TABLE 162. INDONESIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2024-2030 (USD MILLION)
  • TABLE 163. INDONESIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 164. INDONESIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 165. JAPAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 166. JAPAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 167. JAPAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 168. JAPAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 169. JAPAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2023 (USD MILLION)
  • TABLE 170. JAPAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2024-2030 (USD MILLION)
  • TABLE 171. JAPAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2023 (USD MILLION)
  • TABLE 172. JAPAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2024-2030 (USD MILLION)
  • TABLE 173. JAPAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 174. JAPAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 175. MALAYSIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 176. MALAYSIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 177. MALAYSIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 178. MALAYSIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 179. MALAYSIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2023 (USD MILLION)
  • TABLE 180. MALAYSIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2024-2030 (USD MILLION)
  • TABLE 181. MALAYSIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2023 (USD MILLION)
  • TABLE 182. MALAYSIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2024-2030 (USD MILLION)
  • TABLE 183. MALAYSIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 184. MALAYSIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 185. PHILIPPINES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 186. PHILIPPINES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 187. PHILIPPINES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 188. PHILIPPINES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 189. PHILIPPINES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2023 (USD MILLION)
  • TABLE 190. PHILIPPINES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2024-2030 (USD MILLION)
  • TABLE 191. PHILIPPINES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2023 (USD MILLION)
  • TABLE 192. PHILIPPINES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2024-2030 (USD MILLION)
  • TABLE 193. PHILIPPINES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 194. PHILIPPINES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 195. SINGAPORE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 196. SINGAPORE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 197. SINGAPORE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 198. SINGAPORE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 199. SINGAPORE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2023 (USD MILLION)
  • TABLE 200. SINGAPORE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2024-2030 (USD MILLION)
  • TABLE 201. SINGAPORE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2023 (USD MILLION)
  • TABLE 202. SINGAPORE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2024-2030 (USD MILLION)
  • TABLE 203. SINGAPORE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 204. SINGAPORE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 205. SOUTH KOREA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 206. SOUTH KOREA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 207. SOUTH KOREA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 208. SOUTH KOREA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 209. SOUTH KOREA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2023 (USD MILLION)
  • TABLE 210. SOUTH KOREA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2024-2030 (USD MILLION)
  • TABLE 211. SOUTH KOREA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2023 (USD MILLION)
  • TABLE 212. SOUTH KOREA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2024-2030 (USD MILLION)
  • TABLE 213. SOUTH KOREA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 214. SOUTH KOREA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 215. TAIWAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 216. TAIWAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 217. TAIWAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 218. TAIWAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 219. TAIWAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2023 (USD MILLION)
  • TABLE 220. TAIWAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2024-2030 (USD MILLION)
  • TABLE 221. TAIWAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2023 (USD MILLION)
  • TABLE 222. TAIWAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2024-2030 (USD MILLION)
  • TABLE 223. TAIWAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 224. TAIWAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 225. THAILAND VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 226. THAILAND VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 227. THAILAND VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 228. THAILAND VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 229. THAILAND VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2023 (USD MILLION)
  • TABLE 230. THAILAND VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2024-2030 (USD MILLION)
  • TABLE 231. THAILAND VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2023 (USD MILLION)
  • TABLE 232. THAILAND VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2024-2030 (USD MILLION)
  • TABLE 233. THAILAND VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 234. THAILAND VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 235. VIETNAM VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 236. VIETNAM VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 237. VIETNAM VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 238. VIETNAM VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 239. VIETNAM VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2023 (USD MILLION)
  • TABLE 240. VIETNAM VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2024-2030 (USD MILLION)
  • TABLE 241. VIETNAM VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2023 (USD MILLION)
  • TABLE 242. VIETNAM VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2024-2030 (USD MILLION)
  • TABLE 243. VIETNAM VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 244. VIETNAM VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2023 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2024-2030 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2023 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2024-2030 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 254. EUROPE, MIDDLE EAST & AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 257. DENMARK VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 258. DENMARK VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 259. DENMARK VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 260. DENMARK VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 261. DENMARK VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2023 (USD MILLION)
  • TABLE 262. DENMARK VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2024-2030 (USD MILLION)
  • TABLE 263. DENMARK VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2023 (USD MILLION)
  • TABLE 264. DENMARK VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2024-2030 (USD MILLION)
  • TABLE 265. DENMARK VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 266. DENMARK VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 267. EGYPT VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 268. EGYPT VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 269. EGYPT VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 270. EGYPT VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 271. EGYPT VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2023 (USD MILLION)
  • TABLE 272. EGYPT VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2024-2030 (USD MILLION)
  • TABLE 273. EGYPT VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2023 (USD MILLION)
  • TABLE 274. EGYPT VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2024-2030 (USD MILLION)
  • TABLE 275. EGYPT VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 276. EGYPT VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 277. FINLAND VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 278. FINLAND VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 279. FINLAND VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 280. FINLAND VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 281. FINLAND VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2023 (USD MILLION)
  • TABLE 282. FINLAND VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2024-2030 (USD MILLION)
  • TABLE 283. FINLAND VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2023 (USD MILLION)
  • TABLE 284. FINLAND VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2024-2030 (USD MILLION)
  • TABLE 285. FINLAND VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 286. FINLAND VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 287. FRANCE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 288. FRANCE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 289. FRANCE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 290. FRANCE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 291. FRANCE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2023 (USD MILLION)
  • TABLE 292. FRANCE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2024-2030 (USD MILLION)
  • TABLE 293. FRANCE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2023 (USD MILLION)
  • TABLE 294. FRANCE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2024-2030 (USD MILLION)
  • TABLE 295. FRANCE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 296. FRANCE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 297. GERMANY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 298. GERMANY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 299. GERMANY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 300. GERMANY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 301. GERMANY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2023 (USD MILLION)
  • TABLE 302. GERMANY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2024-2030 (USD MILLION)
  • TABLE 303. GERMANY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2023 (USD MILLION)
  • TABLE 304. GERMANY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2024-2030 (USD MILLION)
  • TABLE 305. GERMANY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 306. GERMANY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 307. ISRAEL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 308. ISRAEL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 309. ISRAEL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 310. ISRAEL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 311. ISRAEL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2023 (USD MILLION)
  • TABLE 312. ISRAEL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2024-2030 (USD MILLION)
  • TABLE 313. ISRAEL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2023 (USD MILLION)
  • TABLE 314. ISRAEL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2024-2030 (USD MILLION)
  • TABLE 315. ISRAEL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 316. ISRAEL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 317. ITALY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 318. ITALY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 319. ITALY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTIO